本帖最后由 老马 于 2012-1-13 21:20 编辑
: N& m r w$ H! h% W* q" ?7 W, p
- R6 ~1 \# j' r% l爱必妥和阿瓦斯丁的比较1 A$ z& T1 E* y% |) B6 C0 b
+ k: u4 Q: e: C0 t( k+ Hhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/: \& Z+ M5 b' r, V) E1 i" Z
2 ^4 C# w6 x' g- \6 O) C
8 Z. A4 @7 D8 \0 S& o4 {4 K# d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 B2 _& F# o& R2 \; ^4 K l2 I==================================================
* P4 ?0 a9 Z- e% C+ a" {Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, O; U0 E) i. }7 {4 J* E4 |7 r* w* {Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( h6 @4 F5 l; I7 lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., z9 n3 V# c ~) `' c
|